4.7 Article

COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test

期刊

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 122, 期 -, 页码 576-584

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2022.07.013

关键词

Dengue; COVID-19; SARS-CoV-2; Cross-reactivity; Virus neutralization assay (VNT); enzyme-linked immunosorbent assay; (ELISA); Lateral flow immunoassay (LFIA)

资金

  1. CSIR-India [MLP 130]

向作者/读者索取更多资源

A study found that there is serological cross-reactivity between SARS-CoV-2 and dengue virus, which may affect dengue serodiagnosis and infectivity. In an experiment conducted in a highly dengue-endemic city in India, most of the COVID-19 positive serum samples showed cross-reactivity with dengue virus in rapid immunoassays or enzyme-linked immunosorbent assays and were able to neutralize dengue virus. This suggests that the COVID-19 pandemic may have a protective effect against dengue virus in dengue-endemic areas.
Objectives: Observing the serological cross-reactivity between SARS-CoV-2 and dengue virus (DV), we aimed to elucidate its effect on dengue serodiagnosis and infectivity in a highly dengue-endemic city in India. Methods: A total of 52 COVID-19 (reverse transcription-polymerase chain reaction [RT-PCR] positive) serum samples were tested in rapid lateral flow immunoassays and DV immunoglobulin G (IgG) enzymelinked immunosorbent assay (ELISA) to detect DV or SARS-CoV-2 IgG/immunoglobulin M. The COVID-19 antibody (Ab) positive samples were subjected to a virus neutralization test (Huh7 cells) using DV type 1 (DV1) clinical isolate. Results: Most (93%) of the SARS-CoV-2 Ab-positive serum samples cross-reacted with DV in rapid or ELISA tests. All were DV RNA and nonstructural protein 1 (NS1) antigen-negative. COVID-19 serum samples that were DV cross-reactive neutralized DV1. Of these, 57% had no evidence of DV pre-exposure (DV NS1 Ab-negative). The computational study also supported potential interactions between SARS-CoV-2 Ab and DV1. Conclusion: DV serodiagnosis will be inconclusive in areas co-endemic for both viruses. The COVID-19 pandemic appears to impart a protective response against DV in DV-endemic populations. (c) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据